Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Gross Margin (2020 - 2025)

Vivos Therapeutics' Gross Margin history spans 6 years, with the latest figure at 78.14% for Q4 2025.

  • Quarterly results put Gross Margin at 78.14% for Q4 2025, up 2143.0% from a year ago — trailing twelve months through Dec 2025 was 60.45% (up 45.0% YoY), and the annual figure for FY2025 was 60.44%, up 43.0%.
  • Gross Margin for Q4 2025 was 78.14% at Vivos Therapeutics, up from 58.04% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 80.59% in Q2 2021 to a low of 50.03% in Q1 2025.
  • The 5-year median for Gross Margin is 61.19% (2023), against an average of 63.53%.
  • The sharpest move saw Gross Margin tumbled -1873bps in 2022, then surged 2143bps in 2025.
  • Year by year, Gross Margin stood at 70.71% in 2021, then decreased by -15bps to 60.35% in 2022, then grew by 7bps to 64.32% in 2023, then decreased by -12bps to 56.71% in 2024, then surged by 38bps to 78.14% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 78.14%, 58.04%, and 55.24% for Q4 2025, Q3 2025, and Q2 2025 respectively.